Target intelligence / Profile preview

Multiple wound-healing pathways and cell types

Molecular classification
Other
01

Overview

Wound healing is a complex, multi-stage biological process involving a coordinated sequence of events: hemostasis, inflammation, proliferation, and remodeling (StatPearls, 2023). It requires the interaction of various cell types, including platelets, neutrophils, macrophages, fibroblasts, and endothelial cells, as well as numerous signaling pathways such as the TGF-beta, Wnt/beta-catenin, and Notch pathways (NCBI, 2022). Dysregulation of these pathways can lead to chronic non-healing wounds, such as diabetic foot ulcers, or excessive scarring and fibrosis. While many therapeutic agents aim to accelerate or improve the quality of wound healing, they typically target specific molecular components within this broad system rather than the entire process simultaneously (PubMed, 2021). Understanding the interplay between these multiple pathways and cell types is crucial for developing effective regenerative medicine strategies, though the term itself describes a physiological system rather than a discrete therapeutic target.

Other names
Wound healing processTissue repair pathwaysCutaneous wound healing cascadeWound healing environment
02

Mechanism of action

Therapeutic strategies involve the exogenous application of growth factors, modulation of inflammatory cytokines, and enzymatic degradation of necrotic tissue to transition wounds from a chronic inflammatory state to a proliferative phase (NCBI, 2022).

03

Biological functions

Tissue repairInflammationCell proliferationAngiogenesisExtracellular matrix remodelingImmune response
04

Disease associations

Chronic woundsDiabetic foot ulcersPressure ulcersFibrosisHypertrophic scarringKeloids
05

Safety considerations

Increased risk of malignancy with prolonged growth factor use (e.g., Becaplermin black box warning)Excessive fibrosis or pathological scarringSecondary infection risk at the wound siteSystemic absorption of topical agents leading to off-target effectsImpaired healing if the inflammatory phase is prematurely suppressed
06

Interacting drugs

Becaplermin

4 more in the full profile.

07

Biomarkers

Matrix metalloproteinase-9 (MMP-9)Vascular endothelial growth factor (VEGF)Interleukin-6 (IL-6)Tumor necrosis factor-alpha (TNF-alpha)Tissue inhibitor of metalloproteinases (TIMPs)

Beyond the preview

Go deeper on Multiple wound-healing pathways and cell types.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multiple wound-healing pathways and cell types.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call